2020 Fiscal Year Annual Research Report
A new therapeutic approach to diabetic nephropathy: targeting renal hypoxia by inhibition of sodium-glucose co-transport in the proximal tubule
| Project/Area Number |
19K17759
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
オー ペイ・チェン・コニー 国立研究開発法人国立循環器病研究センター, 研究所, 流動研究員 (30824221)
|
|---|
| Project Period (FY) |
2019-04-01 – 2021-03-31
|
| Keywords | diabetic nephropathy / renal hypoxia / SGLT2 inhibitor / dapagliflozin / kidney |
|---|
| Outline of Annual Research Achievements |
Acute administration of SGLT2 inhibitors in ZFDM rats improved cortical tissue hypoxia in both early and mid stages of diabetic nephropathy and is driven by a reduction in renal oxygen consumption. This ameliorative effect of cortical tissue hypoxia in diabetic nephropathy persists with chronic use of dapagliflozin as evinced by the marked reduction of HIF-1a proteins in treated rats. Chronic treatment increases sensitivity of vessels to prostaglandins and EDHs, and are anti-apoptotic, anti-inflammatory while having no apparent effects on oxidative pathways.
|
